The Clinical Effects of Nicorandil during Percutaneous Coronary Intervention in Patients with Unstable Angina.
10.4070/kcj.2005.35.4.322
- Author:
Ju Han KIM
1
;
Myung Ho JEONG
;
Sang Yup LIM
;
Sang Hyun LEE
;
Yun Sang LEE
;
Kyung Ho YOON
;
Dong Goo KANG
;
Kye Hun KIM
;
Young Joon HONG
;
Hyung Wook PARK
;
Ok Young PARK
;
Weon KIM
;
Young Keun AHN
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. myungho@chollian.net
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Angina;
Nitroglycerin;
Nicorandil;
Angioplasty
- MeSH:
Angina, Unstable*;
Angioplasty;
Blood Platelets;
Coronary Angiography;
Creatine;
Echocardiography;
Follow-Up Studies;
Glycoproteins;
Humans;
Isosorbide Dinitrate;
Male;
Nicorandil*;
Nitroglycerin;
Percutaneous Coronary Intervention*;
Stroke Volume;
Troponin;
Troponin I;
Troponin T
- From:Korean Circulation Journal
2005;35(4):322-327
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES: The purpose of the study was to evaluate the clinical effect of Nicorandil during percutaneous coronary intervention (PCI) in patients with unstable angina (UA). SUBJECTS AND METHODS: Two hundred patients (61+/-10 years, male 143) with UA were randomly assigned to two groups: intravenous Isosorbide dinitrate (Group I, n=100) and intravenous Nicorandil (Group II, n=100). PCI was performed 12-48 hours after infusion of the agents. The post-procedural cardiac enzymes, 6-month MACE (major adverse cardiac event) and left ventricular ejection fraction (LVEF) were compared between the two groups. RESULTS: Successful PCI was performed in 96 patients (Group I=54, Group II=42). Patients requiring either emergent coronary angiography, temporary pacemaker or platelet glycoprotein IIb/IIIa receptor blocker were excluded. No significant differences were observed between the two groups in terms of the clinical and coronary angiographic characteristics. The level of creatine kinase-MB was elevated in 9 (17%) and 6 patients (14%), troponin T in 16 (30%) and 6 (14%) and troponin I in 25 (46%) and 9 (21%) patients of Groups I and II, respectively, after the PCI. The elevation of all troponins was lower in Group II (28 vs. 10 patients, p=0.01). MACE developed in 9 (17%) and 5 (12%) patients of Groups I and II (p=NS), respectively, during the 6-month clinical follow-up. The LVEF was higher in Group II than in Group I on follow-up echocardiography (65.4+/-7.2% vs. 71.0+/-6.7%, p=0.003). CONCLUSION: Nicorandil may have a myocardial protective effect during PCI in patients with UA.
